Cronos Group (TSE:CRON) Trading Down 4.1% – Should You Sell?

Shares of Cronos Group Inc. (TSE:CRON) were down 4.1% during trading on Tuesday . The stock traded as low as C$3.76 and last traded at C$3.77. Approximately 203,340 shares were traded during trading, an increase of 15% from the average daily volume of 177,206 shares. The stock had previously closed at C$3.93.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on CRON shares. TD Securities set a C$4.50 price target on shares of Cronos Group and gave the stock a “buy” rating in a research report on Tuesday, February 24th. TD increased their price objective on shares of Cronos Group from C$4.50 to C$5.50 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of C$4.75.

Cronos Group Trading Down 0.3%

The stock has a market cap of C$1.40 billion, a price-to-earnings ratio of -188.00, a price-to-earnings-growth ratio of 0.12 and a beta of 1.12. The firm’s 50 day moving average is C$3.65 and its two-hundred day moving average is C$3.63. The company has a quick ratio of 24.01, a current ratio of 21.87 and a debt-to-equity ratio of 0.12.

Cronos Group (TSE:CRON) last released its quarterly earnings data on Monday, May 11th. The company reported C$0.06 earnings per share for the quarter. The firm had revenue of C$62.86 million for the quarter. Cronos Group had a negative net margin of 1.29% and a negative return on equity of 0.19%. Equities analysts anticipate that Cronos Group Inc. will post -0.26 EPS for the current year.

Cronos Group Company Profile

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.